Combined modality treatment for stage III non-small cell lung cancer.
There are increasing reports of studies in which combined modality treatment is being tested in stage III non-small cell lung cancer. Randomized trials in which sequential chemoradiotherapy has been compared to radiation alone and in which single agent cisplatin and simultaneous thoracic radiation were compared to radiation are reviewed and discussed. The largest and the most mature phase II trials of preoperative chemotherapy are also included in this review. Similarly the results from recently reported small randomized trials evaluating preoperative treatment are described. Potential future directions for clinical trials are suggested, including the incorporation of new agents in combined modality regimens.
Bonomi
P
P
Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D015996:Survival Rate
D000970:Antineoplastic Agents; D002945:Cisplatin